AbCellera earned a net profit of US$168.6-million, or US59 cents per share on a diluted basis. It generated US$202.7-million in revenues and US$117.2-million in net profit in the same period in 2021.
AbCellera uses a unique mixture of technologies to rapidly crank out antibody after antibody in partnership with pharmaceutical companies. It speeds up the process of isolating and identifying antibodies that immune systems create to fight infections. A key step involves passing cells from a person or animal that has developed an immune response to a disease through a device with hundreds of thousands of tiny chambers. Using artificial intelligence, it tests antibodies produced by cells in each chamber simultaneously to determine which could become drugs.
Like as in monoclonal antibodies? Who is given access to this? The majority are still acting as if it's ban. Are they selling it to the states?